# Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer

> **NCT07025174** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 60 (estimated)

## Conditions studied

- Bile Duct Carcinoma
- Gall Bladder Cancer
- Biliary Tract Cancer
- Cholangiocarcinoma

## Interventions

- **DRUG:** PD-1/CTLA-4 Dual Functional Antibody
- **DRUG:** Gemcitabine, Cisplatin
- **DRUG:** Anlotinib
- **DRUG:** Oxaliplatin + 5-Fluorouracil/Leucovorin

## Key facts

- **NCT ID:** NCT07025174
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07025174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07025174, "Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07025174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*